Prevalence of protective level of hepatitis B antibody 3 years after revaccination in HIV-infected children on antiretroviral therapy

Vaccine

Volumn 29, Issue 23, 2011, Pages 3977-3981

  Lao araya, Mongkol ^a   Puthanakit, Thanyawee ^b   Aurpibul, Linda ^b   Taecharoenkul, Sineenart ^b   Sirisanthana, Thira ^b   Sirisanthana, Virat ^a,b  

^a Faculty of Medicine Chiang Mai University   (Thailand)

^b CHIANG MAI UNIVERSITY   (Thailand)

Author keywords

Hepatitis B vaccine; Human immunodeficiency virus (HIV); Protective antibody

Indexed keywords

ANTIRETROVIRUS AGENT; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE;

ANTIBODY TITER; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CHILD; CONFIDENCE INTERVAL; FEMALE; GEOMETRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGICAL MEMORY; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREDICTOR VARIABLE; PREVALENCE; PRIORITY JOURNAL; REVACCINATION;

ADOLESCENT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOLOGIC MEMORY; MALE; PREVALENCE; TIME FACTORS;

EID: 79955646064     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.03.077     Document Type: Article

References (32)

1. Toussi S.S., Abadi J., Rosenberg M., Levanon D. Prevalence of hepatitis B and C virus infections in children infected with HIV. Clin Infect Dis 2007, 45:795-798.
2. Telatela S.P., Matee M.I., Munubhi E.K. Seroprevalence of hepatitis B and C viral co-infections among children infected with human immunodeficiency virus attending the paediatric HIV care and treatment center at Muhimbili National Hospital in Dar-es-Salaam, Tanzania. BMC Public Health 2007, 7:338.
3. Zhou S., Zhao Y., He Y., Li H., Bulterys M., Sun X., et al. Hepatitis B and hepatitis C seroprevalence in children receiving antiretroviral therapy for human immunodeficiency virus-1 infection in China, 2005-2009. J Acquir Immune Defic Syndr 2010, 54(2):191-196.
4. Thio C.L., Seaberg E.C., Skolasky R., Phair J., Visscher B., Munoz A., et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002, 360(9349):1921-1926.
5. Law W.P., Dore G.J., Duncombe C.J., Mahanontharit A., Boyd M.A., Ruxrungtham K., et al. Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001. AIDS 2003, 17(15):2191-2199.
6. Moss W.J., Clements C.J., Halsey N.A. Immunization of children at risk of infection with human immunodeficiency virus. Bull World Health Organ 2003, 81(1):61-70.
7. Zuin G., Principi N., Tornaghi R., Paccagnini S., Re M., Massironi E., et al. Impaired response to hepatitis B vaccine in HIV infected children. Vaccine 1992, 10(12):857-860.
8. Pessoa S.D., Miyamoto M., Ono E., Gouvea A.F., de Moraes-Pinto M.I., Succi R.C. Persistence of vaccine immunity against hepatitis B virus and response to revaccination in vertically HIV-infected adolescents on HAART. Vaccine 2010, 28(6):1606-1612.
9. Siriaksorn S., Puthanakit T., Sirisanthana T., Sirisanthana V. Prevalence of protective antibody against hepatitis B virus in HIV-infected children with immune recovery after highly active antiretroviral therapy. Vaccine 2006, 24(16):3095-3099.
10. Zanetti A.R., Mariano A., Romano L., D'Amelio R., Chironna M., Coppola R.C., et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 2005, 366(9494):1379-1384.
11. But D.Y., Lai C.L., Lim W.L., Fung J., Wong D.K., Yuen M.F. Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: final report. Vaccine 2008, 26(51):6587-6591.
12. Poovorawan Y., Chongsrisawat V., Theamboonlers A., Bock H.L., Leyssen M., Jacquet J.M. Persistence of antibodies and immune memory to hepatitis B vaccine 20 years after infant vaccination in Thailand. Vaccine 2010, 28(3):730-736.
13. Lu J.J., Cheng C.C., Chou S.M., Hor C.B., Yang Y.C., Wang H.L., Hepatitis B immunity in adolescents and necessity for boost vaccination: 23 years after nationwide hepatitis B virus vaccination program in Taiwan. Vaccine 2009, 27(47):6613-6618.
14. Fitzsimons D., Francois G., Hall A., McMahon B., Meheus A., Zanetti A., et al. Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. Vaccine 2005, 23(32):4158-4166.
15. Wainwright R.B., Bulkow L.R., Parkinson A.J., Zanis C., McMahon B.J. Protection provided by hepatitis B vaccine in a Yupik Eskimo population-results of a 10-year study. J Infect Dis 1997, 175(3):674-677.
16. Puthanakit T., Oberdorfer A., Akarathum N., Kanjanavanit S., Wannarit P., Sirisanthana T., et al. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program. Clin Infect Dis 2005, 41(1):100-107.
17. Lao-araya M., Puthanakit T., Aurpibul L., Sirisanthana T., Sirisanthana V. Antibody response to hepatitis B re-vaccination in HIV-infected children with immune recovery on highly active antiretroviral therapy. Vaccine 2007, 25(29):5324-5329.
18. Aurpibul L., Puthanakit T., Sirisanthana T., Sirisanthana V. Response to measles, mumps, and rubella revaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy. Clin Infect Dis 2007, 45(5):637-642.
19. Puthanakit T., Aurpibul L., Yoksan S., Sirisanthana T., Sirisanthana V. Japanese encephalitis vaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy. Vaccine 2007, 25(49):8257-8261.
20. Cassidy W.M., Watson B., Ioli V.A., Williams K., Bird S., West D.J. A randomized trial of alternative two- and three-dose hepatitis B vaccination regimens in adolescents: antibody responses, safety, and immunologic memory. Pediatrics 2001, 107(4):626-631.
21. Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity. Lancet 2000, 355(9203):561-565.
22. Hepatitis B Vaccines. Wkly Epidemiol Rec 2009, 84(40):405-419.
23. Jack A.D., Hall A.J., Maine N., Mendy M., Whittle H.C. What level of hepatitis B antibody is protective?. J Infect Dis 1999, 179(2):489-492.
24. Geretti A.M., Brook G., Cameron C., Chadwick D., Heyderman R.S., MacMahon E., et al. British HIV Association guidelines for immunization of HIV-infected adults 2008. HIV Med 2008, 9(10):795-848.
25. Obaro S.K., Pugatch D., Luzuriaga K. Immunogenicity and efficacy of childhood vaccines in HIV-1-infected children. Lancet Infect Dis 2004, 4(8):510-518.
26. Mehta N., Cunningham C.K., Flynn P., Pepe J., Obaro S., Kapogiannis B.G., et al. Impaired generation of hepatitis B virus-specific memory B cells in HIV infected individuals following vaccination. Vaccine 2010, 28(21):3672-3678.
27. Landrum M.L., Huppler Hullsiek K., Ganesan A., Weintrob A.C., Crum-Cianflone N.F., Barthel R.V., et al. Hepatitis B vaccine responses in a large U.S. military cohort of HIV-infected individuals: another benefit of HAART in those with preserved CD4 count. Vaccine 2009, 27(34):4731-4738.
28. Abzug M.J., Warshaw M., Rosenblatt H.M., Levin M.J., Nachman S.A., Pelton S.I., et al. Immunogenicity and immunologic memory after hepatitis B virus booster vaccination in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis 2009, 200(6):935-946.
29. Overton E.T., Sungkanuparph S., Powderly W.G., Seyfried W., Groger R.K., Aberg J.A. Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin Infect Dis 2005, 41(7):1045-1048.
30. Cooper C.L., Angel J.B., Seguin I., Davis H.L., Cameron D.W. CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years. Clin Infect Dis 2008, 46(8):1310-1314.
31. Banatvala J., Van Damme P., Oehen S. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine 2000, 19(7-8):877-885.
32. Banatvala J.E., Van Damme P. Hepatitis B vaccine-do we need boosters?. J Viral Hepat 2003, 10(1):1-6.